当前位置: X-MOL 学术Can. J. Infect. Dis. Med. Microbiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Quantitative Anti-HBc in Liver Pathological States in Patients with Chronic Hepatitis B Virus Infection.
Canadian Journal of Infectious Diseases and Medical Microbiology ( IF 2.8 ) Pub Date : 2019-12-27 , DOI: 10.1155/2019/6545642
Zhan-Qing Zhang 1 , Bi-Sheng Shi 2 , Wei Lu 1 , Dan-Ping Liu 1 , Dan Huang 1 , Yan-Ling Feng 3
Affiliation  

Background. Changes of hepatitis B core antigen antibody (anti-HBc) in liver pathological involvement in patients with chronic hepatitis B virus (HBV) infection have not been investigated in detail. This study aimed to explore evolving patterns of anti-HBc following liver pathological states and to investigate validities of anti-HBc for predicting liver pathological states. Methods. 254 HBeAg-positive and 237 HBeAg-negative patients with chronic HBV infection were enrolled. Liver pathological diagnoses referred to Scheuer standard, and anti-HBc was measured using chemiluminescence microparticle immunoassay. Results. Anti-HBc was significantly positively correlated with pathological grades and stages in both HBeAg-positive (rs = 0.312, , and rs = 0.268, ) and HBeAg-negative (rs = 0.270, , and rs = 0.147, ) patients. The medians of anti-HBc in pathological grades of G1, G2, and G3 and stages of S1, S2, S3, and S4 in HBeAg-positive patients were all significantly lower than those in HBeAg-negative patients (all ). The areas under receiver-operating characteristic curves (95% confidence interval) of anti-HBc for predicting pathological grades ≥G2 and ≥G3, and stages ≥S2 and =S4 in HBeAg-positive patients were 0.683 (0.622–0.740) and 0.662 (0.601–0.720), and 0.627 (0.564–0.687) and 0.683 (0.622–0.740), respectively, and in HBeAg-negative patients were 0.681 (0.618–0.740) and 0.702 (0.639–0.760), and 0.569 (0.503–0.633) and 0.630 (0.565–0.691), respectively. Conclusion. Following hepatic aggravation of necroinflammation and progression of fibrosis, anti-HBc increases gradually in HBeAg-positive patients and continues to increase gradually in HBeAg-negative patients, which is a useful but unsatisfactory marker for monitoring pathological states.

中文翻译:

慢性乙型肝炎病毒感染患者肝脏病理状态下的定量抗 HBc。

背景。尚未详细研究慢性乙型肝炎病毒(HBV)感染患者肝脏病理受累中乙型肝炎核心抗原抗体(anti-HBc)的变化。本研究旨在探索肝脏病理状态后抗 HBc 的演变模式,并研究抗 HBc 预测肝脏病理状态的有效性。方法。纳入了 254 名 HBeAg 阳性和 237 名 HBeAg 阴性的慢性 HBV 感染患者。肝脏病理诊断参照 Scheuer 标准,抗 HBc 采用化学发光微粒免疫测定法测定。结果。抗-HBc与HBeAg阳性患者的病理分级和分期显着正相关(r s = 0.312, ,r s  = 0.268, )和 HBeAg 阴性 ( r s  = 0.270, ,r s  = 0.147, )患者。HBeAg阳性患者G1、G2、G3病理分级和S1、S2、S3、S4期抗-HBc的中位数均显着低于HBeAg阴性患者(均为)。在 HBeAg 阳性患者中,抗 HBc 预测病理分级≥G2 和 ≥G3 和阶段 ≥S2 和 =S4 的受试者工作特征曲线下面积(95% 置信区间)分别为 0.683(0.622-0.740)和 0.662( 0.601–0.720)、0.627 (0.564–0.687) 和 0.683 (0.622–0.740),HBeAg 阴性患者分别为 0.681 (0.618–0.740) 和 0.702 (0.639–0.760) 和 0.569 (0.503–0.633)和 0.630 (0.565–0.691),分别。结论。随着肝脏坏死性炎症加重和纤维化进展,HBeAg 阳性患者的抗 HBc 逐渐升高,HBeAg 阴性患者的抗 HBc 逐渐升高,这是监测病理状态的有用但不令人满意的标志物。
更新日期:2019-12-27
down
wechat
bug